Pacira BioSciences enters the final stretch of Q3 with an activist holder on its register, two fresh analyst initiations pulling in opposite directions, and short interest quietly grinding toward an 18-month high — a combination that makes the stock more charged than its flat one-month return suggests.
The most newsworthy structural fact about PCRX right now is that an activist is on the register. Pedro Escudero holds a Schedule 13D position — the form associated with active intent, not passive ownership — at 7.3% of shares, up from 6.83% at the prior filing in March. He has filed four times since August 2025, a pattern of escalating engagement rather than a one-off disclosure. As always with 13D/G filings, the stake is "as last disclosed" around the 5% threshold; holders dropping below that level are not required to file again. But four filings in thirteen months, with the most recent amendment showing an increased stake, suggests this is not a position being quietly unwound.
Short interest tells its own story, and it points the same direction as the activist's accumulation. Bears have been building steadily — short interest has risen nearly 5% over the past month to reach 17.5% of the free float, a level ORTEX classifies as high. The week-on-week gain was modest at 1.75%, but the direction has been consistent since mid-August. The borrow market, however, offers no squeeze pressure. Availability is running at 350% — meaning there are roughly 3.5 shares available to lend for every share already borrowed — well within the normal range and tighter than the 52-week trough of 215% but nowhere near stressed. Cost to borrow has collapsed over the week, falling more than 50% to just 0.55%, after briefly spiking above 1.6% in mid-September. The ORTEX short score sits at 72, in the top decile for short interest intensity, but the lending market is not signalling any imminent stress on those positions. Options, meanwhile, are essentially neutral: the put/call ratio is at 0.51, barely above its 20-day average and nowhere near the 52-week defensive extreme of 0.96.
The Street is divided, and two initiations this week crystallise the split. Oppenheimer's Les Sulewski launched coverage this morning with an Outperform rating and a $32 target — 30% above the current price of $24.70. Leerink Partners initiated two weeks ago at Market Perform with a $28 target, reflecting the more cautious read that EXPAREL's growth runway is constrained. Needham has a Buy at $33; RBC sits at Sector Perform with a $25 target barely above where the stock trades. The consensus rating is Buy, but with a mean target of $30, the implied upside is real only if the bulls are right about EXPAREL coverage wins and the pipeline. The bear case is specific: slow formulary uptake, uncertainty around the Phase 2 ASCEND trial for PCRX-201, and litigation drag. Valuation multiples are undemanding — a P/E below 8x and EV/EBITDA at 5.6x — but the eps_surprise factor score ranks in the 12th percentile, meaning the company has a track record of missing rather than beating, which makes cheap multiples easier to justify than to re-rate on.
The earnings history reinforces that caution. The most recent print on August 4 sent the stock down 7.6% the next day and 9.4% over the following week. The prior release produced a negligible one-day move but still ended the five-day window down 7.2%. Two consecutive five-day post-earnings drawdowns of that magnitude, at a company carrying 17.5% short interest, explain why bears are not rushing to cover. The next report is scheduled for October 30.
What to watch: whether Oppenheimer's initiation attracts follow-on coverage upgrades that shift the consensus balance, and whether short interest continues its slow climb toward 18% of the float ahead of the October print — the gap between a 30% target-implied upside and a high-short-score stock with two consecutive post-earnings selloffs is the tension this stock will be resolving into year-end.
See the live data behind this article on ORTEX.
Open PCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
